Amgen Inc. Announces Promising Results from Phase 2 Obesity Study of MariTide

Amgen Inc., a leading biotechnology company specializing in the development of innovative medicines, has recently presented significant findings from its Phase 2 obesity study of MariTide at the American Diabetes Association’s 85th Scientific Sessions. The study highlights MariTide’s potential as a groundbreaking treatment for obesity, particularly in patients with type 2 diabetes.

Key Findings from the Study

  • Weight Loss Efficacy: The study demonstrated impressive weight loss results, with non-diabetic patients achieving an average of ~20% weight loss and diabetic patients achieving ~17% compared to a placebo group (2.6% and 1.4%, respectively).
  • Sustained Results: Notably, no weight loss plateau was observed at the 52-week mark, suggesting the potential for further weight reduction over time.
  • Cardiometabolic Improvements: Participants experienced significant improvements in cardiometabolic measures, including reductions in blood pressure and lipid parameters.
  • HbA1c Reduction: Diabetic patients saw a robust reduction in HbA1c levels, up to 2.2%, indicating improved blood sugar control.
  • Dosing and Tolerability: Monthly or less frequent dosing of MariTide could enhance treatment adherence. Lower starting doses were found to improve gastrointestinal (GI) tolerability without compromising efficacy.

Adverse Events and Future Studies

The most common adverse events reported were gastrointestinal-related, with discontinuation rates due to GI adverse events reaching up to 7.8% in dose escalation arms. A Phase 1 study indicated high vomiting rates (22.5-24.4%) even with dose escalation. Despite these challenges, the efficacy of MariTide positions it as a strong competitor in the obesity treatment market.

Amgen has announced that the MARITIME Phase 3 Chronic Weight Management Studies are actively enrolling. Additionally, Phase 3 studies targeting individuals with atherosclerotic cardiovascular disease, heart failure, and obstructive sleep apnea are set to begin in 2025.

Company Overview

Amgen Inc. is an independent biotechnology company focused on discovering, developing, manufacturing, and marketing drugs for serious illnesses. The company is listed on the Nasdaq stock exchange, with a market capitalization of approximately $155.74 billion as of June 19, 2025. Amgen’s commitment to innovation in human therapeutics is evident in its development of novel medicines based on cellular and molecular biology.

Market Context

On June 23, 2025, the Dow Jones Industrial Average experienced a positive movement, rising by 0.63% to 42,473.23 points in the NYSE afternoon session. This reflects a broader market context in which Amgen’s promising study results may contribute to investor confidence in the biotechnology sector.

Amgen’s advancements with MariTide underscore the company’s dedication to addressing critical health challenges and enhancing patient outcomes through innovative therapeutic solutions.